Clinical trial in breast cancer patients with bone metastases pretreated for approximately 1 year with a standard zoledronic acid regimen. Looking at the continued effectiveness and safety of giving zoledronic acid every 4 weeks versus every 12 weeks given over 1 year. This study is prospective, double-blind, stratified, multi-center, and two-arm.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
416
4mg IV
Placebo to zoledronic acid
Proportion of Patients Who Experienced at Least One Skeletal Related Event (SRE)
An SRE was defined as a pathologic fracture (vertebral and non-vertebral), spinal cord compression, radiation to bone or surgery to bone.
Time frame: 52 weeks
Time to First SRE
An SRE was defined as a pathologic bone fracture (vertebral and non-vertebral), spinal cord compression, radiation to bone, or surgery to bone. The time to first individual SRE was defined as the date of randomization to the date of first occurrence of any SRE.
Time frame: 52 weeks
Time to First Individual Type of SRE
Types of SREs analyzed were pathologic fractures (vertebral and non-vertebral), spinal cord compression, radiation to bone and surgery to bone. The time to first indvidual SRE was defined as the date of randomization to the date of the first occurrence of any individual SRE.
Time frame: 52 weeks
Change From Baseline in Mean Composite Brief Pain Inventory (BPI) Score
Participants completed a BPI short form which is a 9 item self-administered questionnaire used to evaluate the severity of a participant's pain and the impact of this pain on the participant's daily functioning. The participant rates his or her worst, least, average, and current pain intensity, lists current treatments and perceived effectiveness, and rates the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life on a 10 point scale. The BPI composite score, which was calculated as the average of items 3, 4, 5 and 6 (worst pain, least pain, average pain and pain right now), ranged from 0 (best possible outcome, no pain) to 10 (worst possible outcome, pain as bad as you can imagine). A positive change from baseline indicates worsening.
Time frame: baseline, 52 weeks
Change From Baseline in Mean Analgesic Score
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Providence Alaska Medical Center Cancer Research
Anchorage, Alaska, United States
Heritage Physicians Group Oncology
Hot Springs, Arkansas, United States
The Center for Chest Care
Springdale, Arkansas, United States
Pacific Cancer Medical Center, Inc.
Anaheim, California, United States
South Bay Oncology Hematology Partners
Campbell, California, United States
Bay Area Cancer Research
Concord, California, United States
Pacific Coast Hem/Onc
Fountain Valley, California, United States
Wilshire Oncology Medical Group
La Verne, California, United States
Kenmar Research Institute
Los Angeles, California, United States
North Valley Hematology/Oncology Providence Holy Cross Medical
Northridge, California, United States
...and 82 more locations
The analgesic score indicates the types of pain medication used. The scores range as follows: 0 = none medication; 1 = minor analgesics (aspirin, NSAID, acetaminophen, propoxyphene, etc.); 2 = Tranquilizers, antidepressants, muscle relaxants, and steroids; 3 = Mild narcotics (oxycodone, meperidine, codeine, etc.); and 4 = Strong narcotics (morphine, hydromorphone, etc.). A positive change from baseline indicates worsening.
Time frame: baseline, 52 weeks
Change From Baseline in Urinary N-telopeptide / Creatinine Ratio
Urine samples were collected to obtain n-telopeptide and creatinine values.
Time frame: baseline, 48 weeks
Change From Baseline in Serum Bone Specific Alkaline Phosphatase
Serum samples were collected to obtain bone specific alkaline phosphatase values.
Time frame: baseline, 48 weeks
Skeletal Morbidity Rate
An SMR for a patient was defined as the "number of occurrences" of any (or a particular) SRE allowing for only 1 event in any 3-week interval, divided by the "time at risk" in years. The "number of occurrences" and the "time at risk" were counts of SRE and the time from the randomization date. Counting began from randomization in the way that every counted event was followed by a 20-day period during which no SRE was counted, nor was the time counted as "at risk". For example, if a patient had 1 SRE during the study, the "time at risk" was calculated as the total number of days in the study minus the 20-day follow-up period for that SRE. If a patient had no SRE events, the entire study period was counted as "time at risk". This SMR calculation method had the advantage of avoiding multiple counts of possibly interdependent SREs (e.g. having 1 fracture increases the probability of having a subsequent SRE).
Time frame: 52 weeks